Works matching IS 17762596 AND DT 2023 AND VI 18 AND IP 3
Results: 13
HER2-Low Breast Cancer—Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast.
- Published in:
- 2023
- By:
- Publication type:
- Letter
Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 3, p. 463, doi. 10.1007/s11523-023-00971-9
- By:
- Publication type:
- Article
Uncovering the Burden of Immune-Related Adverse Events in Immunotherapy: Insights from a Nationally Representative Sample.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 3, p. 451, doi. 10.1007/s11523-023-00969-3
- By:
- Publication type:
- Article
P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast.
- Published in:
- 2023
- By:
- Publication type:
- Letter
A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 3, p. 383, doi. 10.1007/s11523-023-00967-5
- By:
- Publication type:
- Article
A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 3, p. 369, doi. 10.1007/s11523-023-00963-9
- By:
- Publication type:
- Article
A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 3, p. 391, doi. 10.1007/s11523-023-00962-w
- By:
- Publication type:
- Article
A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09).
- Published in:
- Targeted Oncology, 2023, v. 18, n. 3, p. 359, doi. 10.1007/s11523-023-00961-x
- By:
- Publication type:
- Article
Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 3, p. 415, doi. 10.1007/s11523-023-00960-y
- By:
- Publication type:
- Article
Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 3, p. 403, doi. 10.1007/s11523-023-00959-5
- By:
- Publication type:
- Article
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 3, p. 441, doi. 10.1007/s11523-023-00958-6
- By:
- Publication type:
- Article
Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 3, p. 327, doi. 10.1007/s11523-023-00957-7
- By:
- Publication type:
- Article
Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 3, p. 425, doi. 10.1007/s11523-023-00955-9
- By:
- Publication type:
- Article